Search HALO
HALOZYME THERAPEUTICS, INC.
Nasdaq · CIK 1159036
Last close109.86
Daily change+2.92 (2.73%)
10 Years gain+797.55%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
HALO · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
73.9Momentum
76.8Acceleration
76.8Confidence
86.0Annual Revenue17
Quarterly Revenue72
Annual CFO17
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth24.8 / 25
Quality18.9 / 25
Capital Efficiency20.0 / 20
Balance Sheet6.6 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 5.3538 percentage points.
Share count reductionDiluted share count declined 4.2868%.
Strong operating leverageOperating income is growing faster than revenue while operating margin expands.
Key Metrics
Revenue Growth TTM56.56%OK
Revenue CAGR 3Y28.38%OK
Gross Margin83.09%OK
Operating Margin58.04%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC36.7%OK
Incremental Operating Margin 3Y66.97%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-4.29%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $1.40B | $1.17B | $469.01M | $651.56M | $644.59M | 83.62% | 33.58% | 46.15% | 16.7% | 123.9M |
| 2025 FY Dec 31, 2024 | $1.02B | $855.91M | $551.48M | $479.06M | $468.37M | 84.3% | 54.32% | 46.13% | 27.32% | 129.42M |
| 2025 FY Dec 31, 2023 | $829.25M | $636.89M | $337.57M | $388.57M | $373.28M | 76.8% | 40.71% | 45.01% | 19.65% | 134.2M |
| 2024 FY Dec 31, 2022 | $660.12M | $520.81M | $267.53M | $240.11M | $235.30M | 78.9% | 40.53% | 35.65% | 27.92% | 140.61M |
| 2023 FY Dec 31, 2021 | $443.31M | $361.90M | $275.90M | $299.44M | $297.98M | 81.64% | 62.24% | 67.22% | 1,362.74% | 146.8M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $1.54B | sum latest 4 fiscal quarters Revenue | OK | 0001159036-26-000104, 0001159036-25-000045 |
| Revenue Growth TTM | 56.56% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001159036-26-000104, 0001159036-25-000045 |
| Revenue CAGR 3Y | 28.38% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001159036-26-000024 |
| Revenue CAGR 5Y | 39.16% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001159036-26-000024 |
| Gross Profit CAGR 3Y | 30.89% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001159036-26-000024 |
| Operating Income Growth | 72.47% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001159036-26-000104, 0001159036-25-000045 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 83.09% | Gross Profit / Revenue | OK | 0001159036-26-000104, 0001159036-25-000045 |
| Operating Margin | 58.04% | Operating Income / Revenue | OK | 0001159036-26-000104, 0001159036-25-000045 |
| ROIC | 36.7% | NOPAT / Average Invested Capital | OK | 0001159036-26-000104, 0001159036-25-000045 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001159036-26-000104 |
| Current Ratio | 2.71x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.08x | (Cash + Short-term Investments) / Total Debt | OK | 0001159036-26-000104 |
| Revenue per Diluted Share | $12.69 | Revenue / Diluted Shares | OK | 0001159036-26-000104, 0001159036-25-000045 |